Tag Archive for: Merck & Co.

Lobbying group Pharmaceutical Research and Manufacturers of America has joined forces with Merck and Bristol-Myers Squibb in filing a lawsuit against the federal government over the price-setting provisions in the Inflation Reduction Act, according to a statement released by the organization Wednesday.

Merck & Co. said on Tuesday its blockbuster immunotherapy Keytruda failed to meet one of the two main goals in a late-stage study testing it as a treatment option for a type of advanced gastric cancer.

Merck finalized its acquisition of immune-focused Prometheus Biosciences for approximately $10.8 billion, scoring five clinical and pre-clinical candidates for inflammatory bowel and immune-mediated diseases on Friday.

Bristol Myers Squibb Co. (BMY.N) on Friday sued the U.S. government in an attempt to halt the Medicare drug price negotiation program that analysts believe will involve one of its top-selling medicines, saying it violates the Fifth and First Amendments to the U.S. Constitution.

BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc. was shown to shrink tumors in close to 30% of participants in a mid-stage lung cancer trial.

Drugmaker Merck & Co. Inc. on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.

Eli Lilly presented the first clinical data on its KRAS G12 inhibitor at the American Association for Cancer Research (AACR) meeting in Orlando on Monday. Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

Tuesday, GSK signed an acquisition agreement with Bellus Health for $2 billion to gain access to the Canadian biotech’s chronic cough candidate camlipixant.

Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, scoring five clinical and pre-clinical candidates for inflammatory bowel and immune-mediated diseases.

Merck & Co. Inc. and Eisai Co. Ltd. said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.